What are the current research-identified risk factors for long‑term therapy with Rinvoq (upadacitinib) 15 mg daily?

Long-Term Risk Factors for Rinvoq (Upadacitinib) 15 mg

Patients taking Rinvoq 15 mg long-term face increased risks of serious infections (especially herpes zoster), venous thromboembolism, major cardiovascular events, and non-melanoma skin cancer, with these risks substantially elevated in those over 50 years with cardiovascular risk factors. 1, 2

Critical Risk Populations Requiring Heightened Monitoring

Age and Cardiovascular Risk Factors

• Patients ≥50 years with ≥1 cardiovascular risk factor represent the highest-risk population for serious adverse events with JAK inhibitors 1, 3
• In this enriched population, approximately 54% of patients in clinical trials fell into this higher-risk category 3
• Age >65 years specifically increases risk of serious infections, though the EMA restriction applies primarily to tofacitinib rather than upadacitinib 1

Venous Thromboembolism (VTE) Risk Factors

Carefully evaluate VTE history before initiating upadacitinib, as the following factors substantially increase thrombotic risk: 1

• Prior VTE events (most significant risk factor)
• Obesity (doubles VTE risk compared to normal weight, with risk increasing proportionally with weight)
• Prolonged immobility (long travel, lower-extremity paralysis, trauma with reduced mobility)
• Hereditary thrombophilia (Factor V Leiden, prothrombin mutation 20210)
• Acquired thrombophilia (antiphospholipid syndrome, active malignancy)
• Concomitant medications: COX-2 inhibitors, prednisone ≥7.5 mg daily, oral contraceptives 1
• Major surgical interventions (neurosurgical, urologic, gynecologic, orthopedic procedures) 1

The FDA label explicitly warns that deep venous thrombosis and pulmonary embolism have been reported in clinical trials, requiring immediate medical attention if symptoms develop 2

Specific Adverse Event Risks

Serious Infections

• Herpes zoster reactivation occurs at incidence rates of 3-4 per 100 patient-years compared to 1 per 100 patient-years with placebo 1
• Upadacitinib 15 mg shows higher rates of herpes zoster than adalimumab across all populations 3, 4
• Serious infection rates increase in higher-risk populations (age ≥50 with cardiovascular risk factors) 3
• Opportunistic infections including tuberculosis reactivation can occur 1, 2

Cardiovascular Events

• Major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular death occur more frequently in higher-risk populations 2, 3
• However, MACE rates with upadacitinib 15 mg are comparable to adalimumab in head-to-head comparisons 3, 5
• Rates range from 0.3-0.6 events per 100 patient-years across rheumatoid arthritis and psoriatic arthritis populations 5
• Current or past smokers face particularly elevated cardiovascular risk 2

Thrombotic Events

• VTE rates with upadacitinib 15 mg remain comparable to adalimumab (0.2-0.4 events per 100 patient-years) 3, 5
• Most patients experiencing VTE events had two or more baseline cardiovascular risk factors 5
• A recent meta-analysis found no significant association between upadacitinib and elevated VTE risk in pooled analyses 6

Malignancy

• Non-melanoma skin cancer (NMSC) risk is elevated with upadacitinib compared to comparators across all populations 3, 4
• Overall malignancy rates (excluding NMSC) are not increased and remain similar across treatment groups 1, 5, 7
• The FDA label mandates periodic skin examinations and limiting sun/UV exposure with protective clothing and broad-spectrum sunscreen 2

Laboratory and Metabolic Abnormalities

• Hepatic disorders, neutropenia, and elevated creatine phosphokinase (CPK) occur more frequently with upadacitinib 3, 4, 6
• These risks demonstrate dose-dependent relationships, though the 15 mg dose shows lower rates than 30 mg 6, 7
• Acne is common (15-21% across studies) and shows dose-dependent increases 6, 8
• Anemia may worsen in some patients due to JAK2 inhibition affecting EPO signaling 1

Gastrointestinal Complications

• Gastrointestinal perforations have been reported, with risk factors including NSAID use, corticosteroids, or history of diverticulitis 2
• Patients should seek immediate care for new-onset abdominal pain, fever, chills, nausea, or vomiting 2

Ophthalmologic Events

• Retinal detachment has been reported in clinical trials 2
• Patients must immediately report any sudden vision changes 2

Contraindications and Special Populations

Absolute Contraindications

• Severe hepatic impairment (Child-Pugh C) 1
• Active chronic HBV infection (positive HBsAg) without concurrent antiviral therapy 1
• Pregnancy and lactation (contraception required during treatment and 4 weeks after; avoid breastfeeding during treatment and 6 days after last dose) 1, 2

Relative Contraindications Requiring Careful Evaluation

• History of recurrent thromboembolic events (unless on anticoagulation) 1
• Current malignancy (except NMSC and cervical carcinoma in situ under treatment) 1
• Active serious infection 2

Required Baseline Screening

Before initiating upadacitinib 15 mg, obtain: 1

• Complete blood count with differential
• Liver enzymes (particularly transaminases)
• Renal function tests
• Lipid panel (unless recently checked)
• Hepatitis B testing (anti-HBs, anti-HBc, HBsAg)
• HIV testing for at-risk populations
• Tuberculosis screening
• Baseline skin examination for NMSC in at-risk patients
• Chest X-ray (unless recently performed)

Long-Term Safety Profile

Five-Year Data

• Safety profile through 5 years remains consistent with the known safety profile, with no new safety risks emerging 4
• Herpes zoster, lymphopenia, CPK elevation, hepatic disorder, and NMSC show numerically higher rates compared to adalimumab over long-term follow-up 4
• Clinical remission rates remain favorable at 5 years (24.6% CDAI remission vs 18.7% with adalimumab) 4

Three-Year Psoriatic Arthritis Data

• No new safety risks emerged with longer-term exposure up to 3 years 7
• Rates of malignancies, MACE, VTE, and deaths remained comparable among upadacitinib and adalimumab groups 7

Common Pitfalls and Clinical Pearls

• Do not combine upadacitinib with biologic DMARDs or potent immunosuppressants (cyclosporine, tacrolimus) due to excessive immunosuppression risk 1
• Avoid live vaccines during treatment; complete vaccinations before initiating therapy 2
• Monitor for medication residue in stool (intact tablets or fragments), which may indicate malabsorption 2
• Avoid grapefruit during treatment due to drug interactions 2
• Do not crush, chew, or split tablets 2
• Consider dose reduction or alternative therapy in patients with creatinine clearance <30 mL/min, though no specific reduction is mandated for upadacitinib unlike other JAK inhibitors 1